Performance Claims & Clinical Benefits
This page displays the performance claims validated through clinical studies and the intended clinical benefits derived from these claims. Performance claims represent specific acceptance criteria tested in clinical validation studies, showing how the device meets performance thresholds. The device enables better objective severity assessment of hidradenitis supurativa with a inter-observer intraclass correlation coefficient (ICC) value of 72.70% which is equal to or greater than the state of the art, based on expert assessment. The device enables better objective severity assessment of hidradenitis supurativa with a inter-class coefficient correlation variability (ICC) value of 10.00% which is lower than the state of the art, based on expert assessment. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 15.12% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 63.06% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 63.06% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 18.43% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 19.38% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 17.00% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 61.71% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 61.71% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 18.43% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 19.38% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 8.30% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 65.65% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 65.65% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 9.37% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.01% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.01% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 10.61% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 73.08% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 73.08% which is greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 26.77% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 57.88% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 25.56% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 46.59% which is greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a specificity value of 23.50% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a specificity value of 62.19% which is greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 32.10% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 56.44% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 25.21% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 44.55% which is greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a specificity value of 24.73% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a specificity value of 61.36% which is greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 12.97% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 61.11% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 16.44% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 52.33% which is greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a specificity value of 15.41% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases with a specificity value of 71.08% which is greater than the state of the art. The device enables better delphi-based consensus of multiple conditions with a (CUS) value of 80.00% which is equal to or greater than the state of the art. The device enables better delphi-based consensus of multiple conditions with a value of 50.00% which is between range the state of the art. The device enables better delphi-based consensus of multiple conditions with a value of 100.00% which is equal to or greater than the state of the art. The device enables better delphi-based consensus of multiple conditions with a value of 100.00% which is equal to or greater than the state of the art. The device enables better delphi-based consensus of multiple conditions with a value of 83.00% which is equal to or greater than the state of the art. The device enables better delphi-based consensus of multiple conditions with a value of 67.00% which is equal to or greater than the state of the art. The device enables better delphi-based consensus of multiple conditions with a (CUS) value of 76.67% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 84.20% which is equal to or greater than the state of the art. The device enables better resource optimisation of multiple conditions with a increase in the adequacy of referrals value of 7.00% which is equal to or greater than the state of the art. The device enables better delphi-based consensus of multiple conditions with a value of 80.00% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 82.00% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a sensitivity value of 57.14% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a specificity value of 93.53% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 42.00% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a negative predictive value (NPV) value of 96.00% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals value of 38.00% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a sensitivity value of 74.00% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a sensitivity value of 74.00% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a specificity value of 67.00% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a specificity value of 67.00% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during in-person care value of 78.60% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during in-person care value of 67.60% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during remote care value of 33.00% which is equal to or greater than the state of the art. The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during remote care value of 67.00% which is equal to or greater than the state of the art. The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 84.37% which is greater than the state of the art. The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 56.00% which is equal to or greater than the state of the art. The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 5 days which is lower than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 82.14% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 78.57% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-3 accuracy value of 89.29% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-5 accuracy value of 89.29% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 97.00% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a sensitivity value of 87.50% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a specificity value of 97.06% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 87.50% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a negative positive value (NPV) value of 97.06% which is equal to or greater than the state of the art. The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 77.00% which is equal to or greater than the state of the art, based on expert assessment. The device enables better objective severity assessment of androgenetic alopecia with a unweighted Kappa value of 73.97% which is equal to or greater than the state of the art, based on expert assessment. The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 47.00% which is equal to or greater than the state of the art, based on expert assessment. The device enables better objective severity assessment of androgenetic alopecia with a unweighted Kappa value of 32.97% which is equal to or greater than the state of the art, based on expert assessment. The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 53.00% which is equal to or greater than the state of the art, based on expert assessment. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 55.00% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-3 accuracy value of 75.84% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-5 accuracy value of 84.22% which is equal to or greater than the state of the art. The device enables better detection of melanoma with a area under the ROC curve (AUC) value of 85.00% which is equal to or greater than the state of the art. The device enables better detection of melanoma with a top-1 accuracy value of 81.00% which is equal to or greater than the state of the art. The device enables better detection of melanoma with a sensitivity value of 93.00% which is equal to or greater than the state of the art. The device enables better detection of melanoma with a specificity value of 80.00% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 89.83% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a sensitivity value of 81.00% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a specificity value of 86.00% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 92.47% which is equal to or greater than the state of the art. The device enables better detection of multiple malignant conditions with a negative positive value (NPV) value of 67.89% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 18.15% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 81.85% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 81.85% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 14.60% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 83.15% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 83.15% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 11.90% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 89.91% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 89.91% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a top-1 accuracy value of 16.66% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a top-1 accuracy value of 22.22% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a sensitivity value of 22.22% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a sensitivity value of 44.44% which is greater than the state of the art. The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a specificity value of 51.85% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a specificity value of 74.07% which is greater than the state of the art. The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 60.70% which is equal to or greater than the state of the art. The device enables better resource optimisation of multiple conditions with a increase in patients that can be managed remotely value of 49.00% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 20.00% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 88.78% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 88.78% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 28.03% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 80.64% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 80.64% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 30.39% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 86.84% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 86.84% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 27.00% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 89.92% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 89.92% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 24.95% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 76.53% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 76.53% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 29.80% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 84.15% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 84.15% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 10.50% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 86.93% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 86.93% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 14.70% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 85.08% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 85.08% which is greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 8.37% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 90.72% which is equal to or greater than the state of the art. The device enables better diagnostic accuracy of multiple conditions with a specificity value of 90.72% which is greater than the state of the art. The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 42.00% which is lower than the state of the art. The device enables better resource optimisation of multiple conditions with a increase in patients that can be managed remotely value of 55.11% which is equal to or greater than the state of the art. The device enables better delphi-based consensus of multiple conditions with a value of 87.00% which is lower than the state of the art. The device enables better delphi-based consensus of multiple conditions with a value of 100.00% which is equal to or greater than the state of the art. Clinical benefits are intended outcomes derived from the device's performance characteristics. Each benefit is supported by multiple performance claims. The device improves accuracy of HCPs during the diagnosis of dermatological conditions. This has a positive impact on patient management and outcomes related to diagnosis and monitoring of patients. top-1 accuracy, sensitivity, specificity The device reduces waiting times for skin-related medical consultations by providing healthcare providers with additional relevant clinical information. This has a positive impact on patient management and outcomes related to the diagnosis and monitoring of patients. reduction in the number of days, increase in patients that can be managed remotely, The device improves the precision of HCPs during the referral. This has a positive impact on patient management, increases the adequacy of referrals and positively impacts outcomes related to diagnosis and monitoring of patients. adequacy of referrals, sensitivity, specificity, adequacy of referrals during in-person care The device improves accuracy of HCPs during the diagnosis of lesions suspicious for skin cancer. This has a positive impact on patient management and outcomes related to diagnosis and monitoring of patients, such as reducing the need for invasive procedures. area under the ROC curve, sensitivity, specificity, positive predictive value, negative predictive value, negative positive value The device improves accuracy of HCPs during the diagnosis of rare diseases. This has a positive impact on patient management and outcomes related to diagnosis and monitoring of patients, especially those suffering from rare diseases. top-1 accuracy, sensitivity, specificity The device measures the degree of involvement of disease objectively, quantitatively, and reproducibly. This increases the precision of healthcare providers during the monitoring of patients. This has a positive impact on patient management and outcomes related to the monitoring of patients and treatment. inter-observer intraclass correlation coefficient, inter-class coefficient correlation variability, , correlation, unweighted Kappa The device improves accuracy of HCPs during the remote diagnosis of skin conditions and the precision of HCPs during the remote referral. This has a positive impact on patient management and outcomes related to diagnosis and monitoring of patients, especially during remote care. , adequacy of referrals during remote care, increase in patients that can be managed remotelyPerformance Claims
Filters
ID Study Device Domain Indications User Group Metric Value Achieved Threshold State of Art Achieved vs SOTA LL5 AIHS4 2025 Plus Objective severity assessment Hidradenitis supurativa Dermatologists 72.70% 47.00% Achieved Exceeds SOTA SDP AIHS4 2025 Plus Objective severity assessment Hidradenitis supurativa Dermatologists 10.00% 10.00% Achieved Below SOTA MRT BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 15.12% 6.36% Achieved Exceeds SOTA 9D7 BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 63.06% NaN% Achieved Below SOTA ZKC BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 63.06% 49.05% Achieved Exceeds SOTA 02A BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 18.43% 6.30% Achieved Exceeds SOTA 5IT BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 71.04% 69.08% Achieved Exceeds SOTA ASM BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 71.04% NaN% Achieved Below SOTA X70 BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 19.38% 4.60% Achieved Exceeds SOTA 0ZD BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 75.83% 76.47% Achieved Below SOTA MJY BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 75.83% NaN% Achieved Below SOTA O4L BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 17.00% 6.36% Achieved Exceeds SOTA GZS BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 61.71% NaN% Achieved Below SOTA 31Q BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 61.71% 41.93% Achieved Exceeds SOTA 81T BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 18.43% 13.00% Achieved Exceeds SOTA 37G BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 71.04% 66.30% Achieved Exceeds SOTA 19H BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 71.04% NaN% Achieved Below SOTA 0H6 BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 19.38% 10.80% Achieved Exceeds SOTA H3D BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 75.83% 70.10% Achieved Exceeds SOTA 0QF BI_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 75.83% NaN% Achieved Below SOTA 6FT BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 8.30% 5.30% Achieved Exceeds SOTA GU0 BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 65.65% NaN% Achieved Below SOTA 47J BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 65.65% 56.18% Achieved Exceeds SOTA W8N BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 9.37% 6.30% Achieved Exceeds SOTA A76 BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 71.01% 72.86% Achieved Below SOTA CUC BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 71.01% NaN% Achieved Below SOTA R9C BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 10.61% 4.60% Achieved Exceeds SOTA 9MI BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 73.08% 77.60% Not Achieved Below SOTA NLW BI_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 73.08% NaN% Achieved Below SOTA DII BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners, Dermatologists 26.77% 6.30% Achieved Exceeds SOTA KOQ BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners, Dermatologists 57.88% NaN% Achieved Below SOTA NK7 BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners, Dermatologists 25.56% 6.30% Achieved Exceeds SOTA DR7 BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners, Dermatologists 46.59% NaN% Achieved Below SOTA 0I1 BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners, Dermatologists 23.50% 4.60% Achieved Exceeds SOTA WAM BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners, Dermatologists 62.19% NaN% Achieved Below SOTA JBB BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners 32.10% 6.30% Achieved Exceeds SOTA ERK BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners 56.44% NaN% Achieved Below SOTA 8PG BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners 25.21% 13.00% Achieved Exceeds SOTA DIK BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners 44.55% NaN% Achieved Below SOTA 99Y BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners 24.73% 10.80% Achieved Exceeds SOTA 8QZ BI_2024 Plus Diagnostic accuracy Rare diseases Primary care practitioners 61.36% NaN% Achieved Below SOTA 4KO BI_2024 Plus Diagnostic accuracy Rare diseases Dermatologists 12.97% 5.30% Achieved Exceeds SOTA S03 BI_2024 Plus Diagnostic accuracy Rare diseases Dermatologists 61.11% NaN% Achieved Below SOTA TG6 BI_2024 Plus Diagnostic accuracy Rare diseases Dermatologists 16.44% 6.30% Achieved Exceeds SOTA OR5 BI_2024 Plus Diagnostic accuracy Rare diseases Dermatologists 52.33% NaN% Achieved Below SOTA Q2D BI_2024 Plus Diagnostic accuracy Rare diseases Dermatologists 15.41% 4.60% Achieved Exceeds SOTA MM8 BI_2024 Plus Diagnostic accuracy Rare diseases Dermatologists 71.08% NaN% Achieved Below SOTA 3OA COVIDX_EVCDAO_2022 Plus Delphi-based consensus Multiple conditions Dermatologists 80.00% 75.00% Achieved Exceeds SOTA ZGP COVIDX_EVCDAO_2022 Plus Delphi-based consensus Multiple conditions Dermatologists 50.00% 75.00% Not Achieved Below SOTA RND COVIDX_EVCDAO_2022 Plus Delphi-based consensus Multiple conditions Dermatologists 100.00% 75.00% Achieved Exceeds SOTA P30 COVIDX_EVCDAO_2022 Plus Delphi-based consensus Multiple conditions Dermatologists 100.00% 75.00% Achieved Exceeds SOTA EZ1 COVIDX_EVCDAO_2022 Plus Delphi-based consensus Multiple conditions Dermatologists 83.00% 75.00% Achieved Exceeds SOTA 3BD COVIDX_EVCDAO_2022 Plus Delphi-based consensus Multiple conditions Dermatologists 67.00% 75.00% Not Achieved Below SOTA NVT COVIDX_EVCDAO_2022 Plus Delphi-based consensus Multiple conditions Dermatologists 76.67% 80.00% Not Achieved Below SOTA EAC DAO_Derivación_PH_2022 Plus Detection Multiple malignant conditions Dermatologists 84.20% 77.80% Achieved Exceeds SOTA 8H5 DAO_Derivación_PH_2022 Plus Resource optimisation Multiple conditions Dermatologists 7.00% 24.00% Not Achieved Below SOTA VCT DAO_Derivación_PH_2022 Plus Delphi-based consensus Multiple conditions Dermatologists 80.00% 70.00% Achieved Exceeds SOTA DX7 DAO_Derivation_O_2022 Plus Detection Multiple malignant conditions Primary care practitioners 82.00% 77.80% Achieved Exceeds SOTA LU4 DAO_Derivation_O_2022 Plus Detection Multiple malignant conditions Primary care practitioners 57.14% 78.40% Not Achieved Below SOTA R9P DAO_Derivation_O_2022 Plus Detection Multiple malignant conditions Primary care practitioners 93.53% 84.00% Achieved Exceeds SOTA 0L2 DAO_Derivation_O_2022 Plus Detection Multiple malignant conditions Primary care practitioners 42.00% N/A Achieved N/A 7ZI DAO_Derivation_O_2022 Plus Detection Multiple malignant conditions Primary care practitioners 96.00% N/A Achieved N/A D62 DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 38.00% 14.00% Achieved Exceeds SOTA CST DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 74.00% 66.30% Achieved Exceeds SOTA 6H0 DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 74.00% NaN% Achieved Below SOTA H4U DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 67.00% 60.10% Achieved Exceeds SOTA 04D DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 67.00% NaN% Achieved Below SOTA DCH DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 78.60% NaN% Achieved Below SOTA DZC DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 67.60% NaN% Achieved Below SOTA LHF DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 33.00% NaN% Achieved Below SOTA 4BO DAO_Derivation_O_2022 Plus Adequacy of referrals Multiple conditions Primary care practitioners 67.00% NaN% Achieved Below SOTA KPQ DAO_Derivation_O_2022 Plus Resource optimisation Multiple conditions Primary care practitioners 84.37% 71.00% Achieved Exceeds SOTA 1M1 DAO_Derivation_O_2022 Plus Resource optimisation Multiple conditions Primary care practitioners 56.00% 71.00% Achieved Below SOTA UGS DAO_Derivation_O_2022 Plus Resource optimisation Multiple conditions Primary care practitioners 5 days 11.5 Achieved Exceeds SOTA LXJ IDEI_2023 Plus Diagnostic accuracy Multiple conditions Dermatologists 82.14% 56.18% Achieved Exceeds SOTA KW3 IDEI_2023 Plus Diagnostic accuracy Multiple conditions Dermatologists 78.57% 50.70% Achieved Exceeds SOTA 7V9 IDEI_2023 Plus Diagnostic accuracy Multiple conditions Dermatologists 89.29% 64.00% Achieved Exceeds SOTA 1S5 IDEI_2023 Plus Diagnostic accuracy Multiple conditions Dermatologists 89.29% 80.00% Achieved Exceeds SOTA FIQ IDEI_2023 Plus Detection Multiple malignant conditions Dermatologists 97.00% 77.80% Achieved Exceeds SOTA GS5 IDEI_2023 Plus Detection Multiple malignant conditions Dermatologists 87.50% 78.40% Achieved Exceeds SOTA 6EP IDEI_2023 Plus Detection Multiple malignant conditions Dermatologists 97.06% 84.00% Achieved Exceeds SOTA PZD IDEI_2023 Plus Detection Multiple malignant conditions Dermatologists 87.50% N/A Achieved N/A V2U IDEI_2023 Plus Detection Multiple malignant conditions Dermatologists 97.06% N/A Achieved N/A JWQ IDEI_2023 Plus Objective severity assessment Androgenetic alopecia Dermatologists 77.00% 60.00% Achieved Exceeds SOTA A1Q IDEI_2023 Plus Objective severity assessment Androgenetic alopecia Dermatologists 73.97% 60.00% Achieved Exceeds SOTA 284 IDEI_2023 Plus Objective severity assessment Androgenetic alopecia Dermatologists 47.00% 60.00% Not Achieved Below SOTA 3OB IDEI_2023 Plus Objective severity assessment Androgenetic alopecia Dermatologists 32.97% 60.00% Not Achieved Below SOTA 7TS IDEI_2023 Plus Objective severity assessment Androgenetic alopecia Dermatologists 53.00% N/A Achieved N/A WGP MC_EVCDAO_2019 Legacy Diagnostic accuracy Multiple conditions Dermatologists 55.00% 50.70% Achieved Exceeds SOTA 6R7 MC_EVCDAO_2019 Legacy Diagnostic accuracy Multiple conditions Dermatologists 75.84% 64.00% Achieved Exceeds SOTA EYP MC_EVCDAO_2019 Legacy Diagnostic accuracy Multiple conditions Dermatologists 84.22% 80.00% Achieved Exceeds SOTA 6U1 MC_EVCDAO_2019 Legacy Detection Melanoma Dermatologists 85.00% 81.00% Achieved Exceeds SOTA JFM MC_EVCDAO_2019 Legacy Detection Melanoma Dermatologists 81.00% 75.40% Achieved Exceeds SOTA ZM8 MC_EVCDAO_2019 Legacy Detection Melanoma Dermatologists 93.00% 73.40% Achieved Exceeds SOTA 4JY MC_EVCDAO_2019 Legacy Detection Melanoma Dermatologists 80.00% 76.20% Achieved Exceeds SOTA 9OD MC_EVCDAO_2019 Legacy Detection Multiple malignant conditions Dermatologists 89.83% 77.80% Achieved Exceeds SOTA BRI MC_EVCDAO_2019 Legacy Detection Multiple malignant conditions Dermatologists 81.00% 78.40% Achieved Exceeds SOTA VFY MC_EVCDAO_2019 Legacy Detection Multiple malignant conditions Dermatologists 86.00% 84.00% Achieved Exceeds SOTA 9G4 MC_EVCDAO_2019 Legacy Detection Multiple malignant conditions Dermatologists 92.47% N/A Achieved N/A Z96 MC_EVCDAO_2019 Legacy Detection Multiple malignant conditions Dermatologists 67.89% N/A Not Achieved N/A 6KX PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 18.15% 6.36% Achieved Exceeds SOTA CZR PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 81.85% NaN% Achieved Below SOTA F16 PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 81.85% 41.93% Achieved Exceeds SOTA 09O PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 14.60% 13.00% Achieved Exceeds SOTA HUG PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 83.15% 66.30% Achieved Exceeds SOTA JZ1 PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 83.15% NaN% Achieved Below SOTA VEF PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 11.90% 10.80% Achieved Exceeds SOTA QX8 PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 89.91% 70.10% Achieved Exceeds SOTA VCN PH_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 89.91% NaN% Achieved Below SOTA I7Y PH_2024 Plus Diagnostic accuracy Rare diseases, Pustular psoriasis Primary care practitioners 16.66% 10.00% Achieved Exceeds SOTA Z90 PH_2024 Plus Diagnostic accuracy Rare diseases, Pustular psoriasis Primary care practitioners 22.22% NaN% Achieved Below SOTA 6YW PH_2024 Plus Diagnostic accuracy Rare diseases, Pustular psoriasis Primary care practitioners 22.22% 13.00% Achieved Exceeds SOTA REV PH_2024 Plus Diagnostic accuracy Rare diseases, Pustular psoriasis Primary care practitioners 44.44% NaN% Achieved Below SOTA 5W2 PH_2024 Plus Diagnostic accuracy Rare diseases, Pustular psoriasis Primary care practitioners 51.85% 10.80% Achieved Exceeds SOTA CH0 PH_2024 Plus Diagnostic accuracy Rare diseases, Pustular psoriasis Primary care practitioners 74.07% NaN% Achieved Below SOTA IP4 PH_2024 Plus Resource optimisation Multiple conditions Primary care practitioners 60.70% 55.00% Achieved Exceeds SOTA WOI PH_2024 Plus Resource optimisation Multiple conditions Primary care practitioners 49.00% 24.00% Not Achieved Exceeds SOTA 61I SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 20.00% 6.36% Achieved Exceeds SOTA YJC SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 88.78% 49.05% Achieved Exceeds SOTA ME3 SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 88.78% NaN% Achieved Below SOTA A84 SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 28.03% 6.30% Achieved Exceeds SOTA 5UM SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 80.64% 69.08% Achieved Exceeds SOTA S2C SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 80.64% NaN% Achieved Below SOTA ZGT SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 30.39% 4.60% Achieved Exceeds SOTA FEH SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 86.84% 76.47% Achieved Exceeds SOTA VFV SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners, Dermatologists 86.84% NaN% Achieved Below SOTA AR8 SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 27.00% 6.36% Achieved Exceeds SOTA 5XF SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 89.92% 41.93% Achieved Exceeds SOTA R7X SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 89.92% NaN% Achieved Below SOTA 7YC SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 24.95% 13.00% Achieved Exceeds SOTA KPM SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 76.53% 66.30% Achieved Exceeds SOTA 2W5 SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 76.53% NaN% Achieved Below SOTA 9YX SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 29.80% 10.80% Achieved Exceeds SOTA FBJ SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 84.15% 70.10% Achieved Exceeds SOTA N2E SAN_2024 Plus Diagnostic accuracy Multiple conditions Primary care practitioners 84.15% NaN% Achieved Below SOTA O0B SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 10.50% 5.00% Achieved Exceeds SOTA 8V3 SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 86.93% 56.18% Achieved Exceeds SOTA UC7 SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 86.93% NaN% Achieved Below SOTA BHO SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 14.70% 6.30% Achieved Exceeds SOTA Q5G SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 85.08% 72.86% Achieved Exceeds SOTA 3GH SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 85.08% NaN% Achieved Below SOTA N50 SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 8.37% 4.60% Achieved Exceeds SOTA B4N SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 90.72% 77.60% Achieved Exceeds SOTA YIO SAN_2024 Plus Diagnostic accuracy Multiple conditions Dermatologists 90.72% NaN% Achieved Below SOTA V2J SAN_2024 Plus Resource optimisation Multiple conditions Dermatologists 42.00% 24.00% Achieved Below SOTA WL4 SAN_2024 Plus Resource optimisation Multiple conditions Dermatologists 55.11% 55.00% Achieved Exceeds SOTA LYP SAN_2024 Plus Delphi-based consensus Multiple conditions Dermatologists 87.00% 70.00% Not Achieved Below SOTA 8MV SAN_2024 Plus Delphi-based consensus Multiple conditions Dermatologists 100.00% 70.00% Achieved Exceeds SOTA Performance Claim Statements
Clinical Benefits
Intended Clinical Benefit
Means of Measure
Estimated Magnitude of Benefit
Associated Performance Claims
Intended Clinical Benefit
Means of Measure
Estimated Magnitude of Benefit
Associated Performance Claims
Intended Clinical Benefit
Means of Measure
Estimated Magnitude of Benefit
Associated Performance Claims
Intended Clinical Benefit
Means of Measure
Estimated Magnitude of Benefit
Associated Performance Claims
Intended Clinical Benefit
Means of Measure
Estimated Magnitude of Benefit
Associated Performance Claims
Intended Clinical Benefit
Means of Measure
Estimated Magnitude of Benefit
Associated Performance Claims
Intended Clinical Benefit
Means of Measure
Estimated Magnitude of Benefit
Associated Performance Claims